The safety and efficacy of arformoterol and formoterol in COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 1, 2010, Pages 17-31

  Hanania, Nicola A ^a   Donohue, James F ^b   Nelson, Harold ^c   Sciarappa, Kenneth ^d   Goodwin, Elizabeth ^d   Baumgartner, R A ^d   Hanrahan, J P ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

Arformoterol; Bronchodilator; COPD; Efficacy; Formoterol; Long acting 2 agonist; Safety

Indexed keywords

ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART ARRHYTHMIA; HEART RATE; HUMAN; INSOMNIA; INSPIRATORY CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEBULIZATION; NERVOUSNESS; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TRANSITION DYSPNEA INDEX; TREATMENT OUTCOME; TREMOR;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; ISOMERISM; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 77949346481     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412550903499498     Document Type: Article

References (42)

1. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007; 4:522-525.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, Zielinski J. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176:532-555.
3. Celli BR and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
5. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276.
6. Foster JA, Yawn BP, Maziar A, Jenkins T, Rennard SI, Casebeer L. Enhancing COPD management in primary care settings. Med Gen Med 2007; 9:24.
7. Miravitlles M, Murio C, Tirado-Conde G, Levy G, Muellerova H, Soriano JB, Ramirez-Venegas A, Ko FW, Canelos-Estrella B, Giugno E, Bergna M, Cherrez I, Anzueto A. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis 2008; 3:803-814.
8. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L, Haddon J, Scalera A. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008;15:13-19.
9. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Jr., Sciurba FC, Thomashow BM, Wise RA. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005; 118:1415.e9-1415.e17.
10. Tsagaraki V, Markantonis SL, Amfilochiou A. Pharmacother-apeutic management of COPD patients in Greece-adherence to international guidelines. J Clin Pharm Ther 2006; 31:369-374.
11. Sivori ML and Raimondi GA. [Survey of chest physicians regarding COPD diagnosis and treatment]. Medicina (B Aires) 2004; 64:113-119.
12. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
13. Donohue JF, Hanania NA, Sciarappa K, Goodwin E, Grogan DR, Baumgartner RA, Hanrahan JP. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety. Thera Adv Respir Dis 2008; 2:37-48.
14. Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, is-Mize K. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med 2008; 102:189-197.
15. Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo-and active-controlled trial. Clin Ther 2007; 29:261-278.
16. Hanrahan J, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008; 5:25-34.
17. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97:1014-1020.
18. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Jr., Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
19. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
20. Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K. Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. Therapeutic Advances in Respiratory Disease 2008; 2:199-208.
21. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
22. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
23. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335-371
24. Brovana TM (arformoterol tartrate) Inhalation Solution [package insert]. 2007.
25. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277:925-926.
26. Fletcher C. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960; 2:1665.
27. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758.
28. Sciurba F, Baumgartner RA, Sciarappa K, Benzo RP, Hanra-han JP. Degree of exercise limitation in COPD: impact on 6-minute walk in response to long-acting beta-agonist (LABA) treatment (Abstract). Eur Respir J 2007; 30:76S.
29. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
30. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van Der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
31. FDA and Center for Drug Evaluation and Research. Guidance for industry: E9 statistical priciples for clinical trials. 1998; 1-43.
32. MedDRA and MSSO. The medical dictionary for regulatory activities. http://www meddramsso com/MSSOWeb/index htm; 2008.
33. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
34. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456.
35. Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005; 18:19-22.
36. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61:122-128.
37. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, Bengtsson T, Rabe KF. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99:1511-1520.
38. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della CG. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-1069.
39. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52:67-71.
40. Halpin DM, Peterson S, Larsson TP, Calverley PM. Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respir Med 2008; Nov; 102(11):1615-1624.
41. Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, StubbingD, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003; 56:1170-1176.
42. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: A 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119:1347-1356.